VEGFA and retinopathy of prematurity: The off-label intravitreal injection of anti-VEGF agents such as conbercept (KH902; Chengdu Kanghong Biotech Co, Ltd, Sichuan, China), bevacizumab (Genentech, Inc, South San Francisco, CA), ranibizumab (Genentech, Inc and Novartis International AG, Basel, Switzerland), and aflibercept (Regeneron Pharmaceuticals Inc) for ROP treatment has been reported in recent years and shown to be efficacious [9–13].